SRR1341521
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.408
- TNFA_SIGNALING_VIA_NFKB+0.404
- KRAS_SIGNALING_DN+0.341
- APICAL_SURFACE+0.283
- COAGULATION+0.257
- APOPTOSIS+0.251
- INFLAMMATORY_RESPONSE+0.240
- XENOBIOTIC_METABOLISM+0.235
- HYPOXIA+0.223
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.213
Top 10 suppressed
- G2M_CHECKPOINT-0.437
- MYC_TARGETS_V1-0.428
- E2F_TARGETS-0.411
- PROTEIN_SECRETION-0.387
- UNFOLDED_PROTEIN_RESPONSE-0.291
- MTORC1_SIGNALING-0.275
- DNA_REPAIR-0.269
- MITOTIC_SPINDLE-0.266
- PI3K_AKT_MTOR_SIGNALING-0.242
- ANDROGEN_RESPONSE-0.222
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1391639 | GTEX | — | 0.938 |
| 2 | SRR1491293 | GTEX | — | 0.875 |
| 3 | SRR1443895 | GTEX | — | 0.851 |
| 4 | SRR659780 | GTEX | — | 0.840 |
| 5 | SRR1394755 | GTEX | — | 0.839 |
| 6 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.833 |
| 7 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.831 |
| 8 | SRR1475909 | GTEX | — | 0.830 |
| 9 | SRR1381757 | GTEX | — | 0.828 |
| 10 | SRR5903552 | — | cohortA1 | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.408 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.404 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.341 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.283 | Temsirolimus | — uncovered |
| COAGULATION | 0.257 | Binimetinib | — uncovered |
| APOPTOSIS | 0.251 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.235 | Inavolisib | — uncovered |
| HYPOXIA | 0.223 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.213 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.189 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.185 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.171 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.164 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.162 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.153 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.147 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.144 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.143 | Remibrutinib | — uncovered |